美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

猴痘概念

2,024.54

-7.1163-0.35%

漲家數：4

跌家數：6

平家數：1

市盈率：- -

高：2,052.89

開：2,052.89

低：2,016.27

收：2,031.66

成交量：2,233.05萬

成交額：10.59億

市值：2,240.97億

流通市值：2,234.03億

資料載入中...

Leerink基於增長勢頭改善，給予Viatris「跑贏大盤」評級

Assembly Biosciences有望獲得高達2.8億美元里程碑付款及美國境外特許權使用費

Assembly Biosciences旗下Gs-1179預計2026年底前將推進至生殖器皰疹二期臨床試驗階段

Assembly Biosciences：吉利德獨享HSV HPI項目臨床開發與商業化權利

Assembly Biosciences行使與吉利德關於HSV解旋酶-引物酶抑制劑項目的美國利潤分成選擇權

吉利德科學(GILD)股票9月8日盤中下跌3.26%：釋放什麼信號？

TradingKey中文

第4次更新-鑑於市場供應存在擔憂，美國食品藥品監督管理局正與製造商合作，以增加雌激素貼片的供應量

Emergent BioSolutions圓滿完成7500萬美元優先無擔保票據回購

Emergent BioSolutions獲增購Cyfendus（Av7909）合同修訂——SEC文件披露

BUZZ——美國股市動態-Fervo Energy、Myriad Genetics、Emergent BioSolutions

Emergent因獲得2400萬美元炭疽疫苗訂單股價上漲

Emergent BioSolutions 獲得長期供應合同：有效期至2029年，附兩年續約選擇權

美國食品藥品監督管理局（FDA）批准吉利德治療艾滋病的每日一次複方片劑

美國FDA批准吉利德科學Bixlenvo™上市：每日單片方案為病毒學抑制HIV成人患者提供新選擇，涵蓋複雜治療方案人群

Shield Therapeutics宣佈全面接管ACCRUFeR美國商業化運營

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/BK4583/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","market":"US","secType":"PLATE","nameCN":"猴痘概念","latestPrice":2024.5422,"timestamp":1789156799999,"preClose":2031.6586,"halted":0,"volume":22330540,"delay":0,"changeRate":-0.003503,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-7.116333,"latestTime":"09-11 16:00:00 EDT","open":2052.8862,"high":2052.8862,"low":2016.2698,"amount":1059245261.617174,"amplitude":0.018023,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.542352,"peRate":-74.230044,"turnoverRate":0.008268,"increases":4,"decrements":6,"flats":0,"marketCap":224097157967.5,"floatMarketCap":223402998500.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","high":2052.8862,"amplitude":0.018023,"preClose":2031.6586,"low":2016.2698,"pbRate":"6.542352","latestPrice":2024.5422,"volume":22330540,"delay":0,"open":2052.8862,"prevYearClose":1682.3505,"prevWeekClose":2112.7637,"prevMonthClose":2060.2607,"prevQuarterClose":1802.0435,"fiveDayClose":2118.1284,"twentyDayClose":1957.7635,"sixtyDayClose":1802.5063,"secType":"PLATE","market":"US","turnoverRate":0.008268,"peRate":-74.230044,"marketCap":224097157967.5,"floatMarketCap":223402998500.5,"timestamp":1789156799999,"nameCN":"猴痘概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4583\",,,,undefined,":{"bkCode":"BK4583","up":4,"down":6,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4583\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666580494","title":"Leerink基於增長勢頭改善，給予Viatris「跑贏大盤」評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2666580494","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666580494?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:48","pubTimestamp":1788954528,"startTime":"0","endTime":"0","summary":"BUZZ-Leerink基于增长势头改善，给予Viatris“跑赢大盘”评级9月9日-** 利林克合伙公司（Leerink Partners）首次覆盖制药公司维亚特里斯（Viatris，VTRS.O），给予“跑赢大盘”评级，目标价为20美元** 该券商预计，在连续三年下滑后，2026年该公司营收和调整后EBITDA将实现增长，其预测值接近公司预期和市场预期的上限** 认为随着维亚特里斯仿制药业务趋","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nL4S45110L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2087621335.USD","LU1839511570.USD","BK4583","BK4585","BK4007","VTRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136308873","title":"Assembly Biosciences有望獲得高達2.8億美元里程碑付款及美國境外特許權使用費","url":"https://stock-news.laohu8.com/highlight/detail?id=1136308873","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136308873?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:02","pubTimestamp":1788897732,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前披露，其在海外市场具备资格获取最高达2.8亿美元的里程碑款项，外加相应特许权使用费收入。据悉，这家生物科技企业所预期的资金流入将源自美国以外地区。对Assembly Biosciences而言，这笔潜在收入不仅反映其管线资产的外部合作价值，也可能为其后续研发投入提供坚实支撑。市场人士认为，此类非美国市场的收益结构有助于分散地域风险，增强公司财务韧性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","LU0965509283.SGD","ASMB","BK4585","LU0889565916.HKD","LU0114720955.EUR","BIB","BK4532","LU1778281490.HKD","LU0823416689.USD","BK4568","IE0002270589.USD","LU2468319806.SGD","IE00BZ1G4Q59.USD","BK4588","LU1037948897.HKD","LU1430594728.SGD","LU1934455194.USD","LU2089984988.USD","LU2357627491.SGD","MEDI","SG9999015978.USD","BK4550","LU0058720904.USD","LU1674673428.USD","LU0965509101.SGD","LU1037948541.HKD","LU0861579265.USD","LU2087621335.USD","LU1023059063.AUD","LU1066051498.USD","BK4566","IE00B19Z3581.USD","LU0859254822.USD","LU1061106388.HKD","LU0882574055.USD","LU1585245621.USD","LU1934455277.USD","SG9999015986.USD","BK4578","LU0109394709.USD","SG9999015945.SGD","BK4583","SG9999015952.SGD","LU2112291526.USD","IE00B3T34201.USD","LU0320765992.SGD","IBB","GILD","LU1839511570.USD","TMED","IE00BSNM7G36.USD","BBH","IE00B7SZLL34.SGD","LU0965508806.USD","LU1066053197.SGD","LU1057294990.SGD","BK4139","LU2324357040.USD","IE00BKVL7J92.USD","LU0289739699.SGD","LU0965509010.AUD","LU1674673691.USD","LU1571399168.USD","LU0234570918.USD","TBXU","LU1934455863.HKD","IBBQ","LU0122379950.USD","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154623157","title":"Assembly Biosciences旗下Gs-1179預計2026年底前將推進至生殖器皰疹二期臨床試驗階段","url":"https://stock-news.laohu8.com/highlight/detail?id=1154623157","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154623157?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:02","pubTimestamp":1788897731,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前宣布，其研发管线中的候选药物Gs-1179有望在2026年年底之前顺利迈入针对生殖器疱疹的二期临床试验阶段。生殖器疱疹作为一种常见的性传播感染疾病，全球患者群体庞大，对创新疗法的需求十分迫切。Assembly Biosciences正积极加速该药物的研发进程，以期尽早为患者带来新的治疗选择。业内分析人士指出，若Gs-1179能够顺利通过后续试验的严格考验，将可能重塑该适应症的市场格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","LU1037948541.HKD","LU1037948897.HKD","BK4566","TMED","LU0859254822.USD","LU0861579265.USD","BK4583","LU1674673428.USD","IE00B3T34201.USD","LU1839511570.USD","LU0289739699.SGD","BK4585","BMED","LU0823416689.USD","SG9999015945.SGD","GILD","LU0234570918.USD","LU1778281490.HKD","LU2468319806.SGD","SG9999015978.USD","BK4588","IE00B19Z3B42.SGD","IE00BKVL7J92.USD","LU2324357040.USD","IE0002270589.USD","LU1934455277.USD","LU2357627491.SGD","LU0122379950.USD","LU0965508806.USD","LU1934455863.HKD","BK4568","IE00B19Z3581.USD","LU0320765992.SGD","IE00BZ1G4Q59.USD","LU0965509283.SGD","LU2112291526.USD","SG9999015986.USD","IBB","LU1934455194.USD","LU0114720955.EUR","LU0889565916.HKD","BK4578","IBBQ","BK4532","LU1430594728.SGD","TBXU","LU0882574055.USD","LU0965509010.AUD","LU1066051498.USD","LU1571399168.USD","LU1585245621.USD","LU1674673691.USD","IE00B7SZLL34.SGD","LU2087621335.USD","LU0109394709.USD","BK4139","ASMB","IE00BSNM7G36.USD","BIB","LU0058720904.USD","LU1057294990.SGD","LU0965509101.SGD","LU1061106388.HKD","LU1066053197.SGD","MEDI","BK4550","BBH","LU1023059063.AUD","SG9999015952.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115029168","title":"Assembly Biosciences：吉利德獨享HSV HPI項目臨床開發與商業化權利","url":"https://stock-news.laohu8.com/highlight/detail?id=1115029168","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115029168?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:01","pubTimestamp":1788897702,"startTime":"0","endTime":"0","summary":"Assembly Biosciences宣布，吉利德科学已保留其HSV HPI项目的独家临床开发及商业化权利。这一决定标志着双方合作进一步深化，吉利德将全权主导该项目的后续推进与市场布局。对于Assembly Biosciences而言，此举不仅明确了合作伙伴的战略优先级，也为其自身聚焦其他管线资源提供了更大灵活性。业内观察人士指出，HSV HPI项目的独家授权，反映了吉利德在抗病毒治疗领域持续加码的雄心，同时也凸显了该类创新疗法在未被满足的医疗需求中所蕴含的巨大潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIB","LU0058720904.USD","LU0234570918.USD","LU0859254822.USD","LU1934455194.USD","SG9999015952.SGD","SG9999015986.USD","LU1057294990.SGD","LU1934455277.USD","LU0109394709.USD","LU0889565916.HKD","IE00B19Z3B42.SGD","LU1066051498.USD","IE00B3T34201.USD","IE00B7SZLL34.SGD","LU0965509101.SGD","ASMB","LU1061106388.HKD","LU2089984988.USD","LU1430594728.SGD","GILD","LU0965509283.SGD","BMED","IE00BSNM7G36.USD","SG9999015945.SGD","MEDI","BK4532","LU1674673691.USD","BK4139","SG9999015978.USD","LU0823416689.USD","BK4585","LU2112291526.USD","LU1585245621.USD","LU1066053197.SGD","TBXU","LU0122379950.USD","LU0114720955.EUR","IE00BZ1G4Q59.USD","BK4566","LU1037948541.HKD","LU1571399168.USD","LU2468319806.SGD","LU1037948897.HKD","LU0320765992.SGD","LU2087621335.USD","LU0965509010.AUD","LU1674673428.USD","BK4550","IE00BKVL7J92.USD","LU0882574055.USD","TMED","IBBQ","BK4588","LU0289739699.SGD","IE00B19Z3581.USD","BK4583","LU0861579265.USD","BK4568","LU1778281490.HKD","LU2357627491.SGD","LU1023059063.AUD","LU2324357040.USD","IE0002270589.USD","LU1839511570.USD","LU1934455863.HKD","LU0965508806.USD","IBB","BK4578","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179230759","title":"Assembly Biosciences行使與吉利德關於HSV解旋酶-引物酶抑制劑項目的美國利潤分成選擇權","url":"https://stock-news.laohu8.com/highlight/detail?id=1179230759","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179230759?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:01","pubTimestamp":1788897669,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司已正式行使与吉利德科学就HSV解旋酶-引物酶抑制剂项目达成的美国利润分成选择权。这一战略举措标志着双方合作进入新阶段，有望加速该抗病毒疗法的临床开发与商业化进程。通过行使该选择权，Assembly Biosciences将能够分享该药物在美国市场的未来收益，同时借助吉利德在抗病毒领域的深厚积累与市场渠道，共同推进这一潜在重磅药物的落地。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0859254822.USD","TMED","ASMB","BK4566","BK4532","LU1571399168.USD","LU0882574055.USD","SG9999015945.SGD","SG9999015978.USD","LU1037948541.HKD","BK4578","IE00BKVL7J92.USD","LU1066051498.USD","IBBQ","IE00B19Z3B42.SGD","LU1430594728.SGD","LU1934455194.USD","LU2089984988.USD","LU2112291526.USD","IBB","IE00BZ1G4Q59.USD","LU0058720904.USD","LU0861579265.USD","LU0965509101.SGD","LU0320765992.SGD","LU1023059063.AUD","LU1839511570.USD","MEDI","LU1066053197.SGD","BBH","LU1674673691.USD","BIB","LU1674673428.USD","LU0109394709.USD","LU1061106388.HKD","LU1057294990.SGD","LU0289739699.SGD","LU0823416689.USD","BK4583","IE00BSNM7G36.USD","LU1934455277.USD","LU1778281490.HKD","BK4550","LU2087621335.USD","SG9999015986.USD","BMED","BK4139","BK4588","LU2324357040.USD","LU0122379950.USD","LU0965509283.SGD","TBXU","LU0234570918.USD","LU0965509010.AUD","LU0114720955.EUR","SG9999015952.SGD","IE00B19Z3581.USD","LU2357627491.SGD","LU2468319806.SGD","BK4585","LU0965508806.USD","IE0002270589.USD","LU1934455863.HKD","IE00B3T34201.USD","IE00B7SZLL34.SGD","LU1037948897.HKD","GILD","LU1585245621.USD","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374570","title":"吉利德科學(GILD)股票9月8日盤中下跌3.26%：釋放什麼信號？","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374570","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374570?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 01:16","pubTimestamp":1788887780,"startTime":"0","endTime":"0","summary":"• 吉利德在经历了长达数月的持续上涨后，因获利回吐而出现回调。\n• 强劲的第二季度营收主要受其旗舰 HIV 和 Trodelvy 产品线的推动。\n• 分析师维持“买入”评级，平均目标价为 157.79 美元。","market":"nz","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262156554-market-movers-gild-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","TMED","LU1037948541.HKD","LU0122379950.USD","LU2324357040.USD","SG9999015986.USD","IE00BKVL7J92.USD","BBH","LU1778281490.HKD","GILD","IE00B19Z3B42.SGD","LU0965508806.USD","LU2112291526.USD","LU1571399168.USD","IE0002270589.USD","BK4585","LU0058720904.USD","IE00B19Z3581.USD","LU1934455277.USD","IBB","SG9999015952.SGD","BK4578","BK4583","LU0882574055.USD","SG9999015945.SGD","BIB","BK4568","LU0859254822.USD","LU1674673428.USD","LU1430594728.SGD","LU0823416689.USD","BK4532","IE00B7SZLL34.SGD","MEDI","LU1839511570.USD","IBBQ","BMED","LU0114720955.EUR","IE00BSNM7G36.USD","LU0109394709.USD","LU1023059063.AUD","SG9999015978.USD","LU0965509101.SGD","LU1674673691.USD","LU2087621335.USD","IE00BZ1G4Q59.USD","LU0861579265.USD","LU0289739699.SGD","LU0320765992.SGD","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664804697","title":"第4次更新-鑑於市場供應存在擔憂，美國食品藥品監督管理局正與製造商合作，以增加雌激素貼片的供應量","url":"https://stock-news.laohu8.com/highlight/detail?id=2664804697","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664804697?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 05:02","pubTimestamp":1788469322,"startTime":"0","endTime":"0","summary":"第4次更新-鉴于市场供应存在担忧，美国食品药品监督管理局正与制造商合作，以增加雌激素贴片的供应量在第10段中补充了拜耳的回应Sriparna Roy路透9月3日-美国卫生监管机构周四表示，在接到患者反映难以及时获得该药物的报告后，该机构正与全部六家制造商合作，以增加用于治疗更年期症状的雌二醇透皮贴片的供应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nL4S44V1QC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","VTRS","BK4588","LU1839511570.USD","BK4007","AMRX","LU2087621335.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178687061","title":"Emergent BioSolutions圓滿完成7500萬美元優先無擔保票據回購","url":"https://stock-news.laohu8.com/highlight/detail?id=1178687061","media":"美股速递","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178687061?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 19:49","pubTimestamp":1788436160,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions（EBS）今日宣布，已顺利完成总额达7500万美元的优先无担保票据回购计划。这一财务操作标志着该公司在优化资本结构方面迈出了坚实一步。此次回购涉及的是公司此前发行的优先无担保债券，其回购价格及相关条款均符合市场惯例与公司既定策略。通过此举，Emergent BioSolutions不仅有效降低了未来的利息负担，还进一步增强了资产负债表的灵活性。该公司管理层表示，此次回购体现了其对股东价值创造的持续承诺，未来将继续审慎评估各类资本配置机会，以支持核心业务的长期增长与创新。分析人士认为，此举或将对公司短期财务指标产生积极影响，并提升投资者信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EBS","BK4583","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149776488","title":"Emergent BioSolutions獲增購Cyfendus（Av7909）合同修訂——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1149776488","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149776488?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 04:15","pubTimestamp":1788293710,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions（纽交所代码：EBS）于近日向美国证券交易委员会（SEC）提交了一份文件，披露其合同修订情况。\n该修订涉及该公司旗下炭疽疫苗产品Cyfendus（Av7909）的额外采购。根据修订条款，采购方将在原有基础上追加订购更多剂量的Cyfendus。\n这笔增购交易的具体金额和交付时间表尚未在文件中详细披露。公司方面表示，此次合同修改反映了采购方对该疫苗产品的持续需求。\n文件提交后，市场对此消息暂无重大反应。Emergent BioSolutions是一家专注于公共卫生防护领域的生物制药公司，其产品线涵盖炭疽、天花等生物威胁相关疫苗及治疗药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","EBS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664035851","title":"BUZZ——美國股市動態-Fervo Energy、Myriad Genetics、Emergent BioSolutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2664035851","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664035851?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 21:14","pubTimestamp":1788268461,"startTime":"0","endTime":"0","summary":"在股市历史上表现疲软的月份伊始，居高不下的债券收益率和上涨的油价令投资者望而却步。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nL4S44T18L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EBS","MYGN","BK4139","BK4133","BK4583","FRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664859352","title":"Emergent因獲得2400萬美元炭疽疫苗訂單股價上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2664859352","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664859352?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 20:17","pubTimestamp":1788265021,"startTime":"0","endTime":"0","summary":"BUZZ-Emergent因获得2400万美元炭疽疫苗订单股价上涨9月1日-** 制药公司Emergent BioSolutions（EBS.N）的股价在盘前交易中上涨3.8%，至6.33美元** 该公司从美国生物医学高级研究与发展局（BARDA）获得了一份价值约2400万美元的订单，将提供其Cyfendus疫苗用于炭疽病防控** “Cyfendus”于2023年获批，是一种两剂疫苗，适用于疑似或","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nL4T44T14Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","EBS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143626034","title":"Emergent BioSolutions 獲得長期供應合同：有效期至2029年，附兩年續約選擇權","url":"https://stock-news.laohu8.com/highlight/detail?id=1143626034","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143626034?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 19:56","pubTimestamp":1788177374,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions宣布，其长期供应协议自2026年10月1日起正式生效，并将持续至2029年9月30日。这份合同还附带了一项重要条款——在现有期限届满后，可选择续约两年。此举无疑为该公司未来的业务稳定性提供了坚实保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EBS","BK4139","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662036374","title":"美國食品藥品監督管理局（FDA）批准吉利德治療艾滋病的每日一次複方片劑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662036374","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662036374?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 05:50","pubTimestamp":1787867453,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）批准吉利德治疗艾滋病的每日一次复方片剂路透8月27日-吉利德科学公司周四表示，美国食品和药物管理局已批准该公司研发的每日一次口服复方药GILD.O，用于治疗HIV病毒载量已降至极低水平的成人患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4S44O24V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BBH","IE00B3T34201.USD","IE00B7SZLL34.SGD","TMED","LU1571399168.USD","LU1674673691.USD","IE00BZ1G4Q59.USD","LU0889565916.HKD","LU0861579265.USD","LU1066053197.SGD","LU2112291526.USD","SG9999015945.SGD","SG9999015986.USD","LU1430594728.SGD","IE00BKVL7J92.USD","IBBQ","IE00B19Z3581.USD","LU0823416689.USD","GILD","LU1037948541.HKD","LU2324357040.USD","LU1778281490.HKD","SG9999015978.USD","BIB","BK4568","LU1023059063.AUD","LU0114720955.EUR","LU0965509283.SGD","LU1934455277.USD","IE0002270589.USD","LU0289739699.SGD","LU1061106388.HKD","LU2468319806.SGD","BK4532","LU0965508806.USD","TBXU","BK4139","LU1839511570.USD","MEDI","BMED","LU0109394709.USD","LU1934455194.USD","BK4585","SG9999015952.SGD","LU1037948897.HKD","LU0965509101.SGD","LU0058720904.USD","BK4566","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198194055","title":"美國FDA批准吉利德科學Bixlenvo™上市：每日單片方案為病毒學抑制HIV成人患者提供新選擇，涵蓋複雜治療方案人群","url":"https://stock-news.laohu8.com/highlight/detail?id=1198194055","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198194055?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 05:49","pubTimestamp":1787867358,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局正式批准了吉利德科学旗下新药Bixlenvo。这款每日一次的单片制剂，专为病毒学抑制状态的HIV成人感染者设计——即便是那些正在接受复杂治疗方案的病患，也适用这一新选项。此项获批标志着HIV治疗领域又添一枚重要砝码。Bixlenvo以单片复方形式呈现，将给药频率与用药负担同步压缩，患者无需再面对繁琐的多药组合。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015986.USD","BK4566","LU0320765992.SGD","LU0965509101.SGD","IBBQ","LU0965509283.SGD","LU0109394709.USD","SG9999015952.SGD","LU1934455863.HKD","LU0058720904.USD","LU1585245621.USD","LU0889565916.HKD","SG9999015978.USD","LU0122379950.USD","LU2089984988.USD","BK4583","BBH","BK4585","LU0289739699.SGD","LU1839511570.USD","BK4568","LU1674673691.USD","IE00B19Z3581.USD","IBB","LU1057294990.SGD","LU1037948541.HKD","LU1061106388.HKD","SG9999015945.SGD","IE00B19Z3B42.SGD","LU0859254822.USD","GILD","LU1778281490.HKD","LU0823416689.USD","BK4139","IE00BZ1G4Q59.USD","LU1934455277.USD","LU2357627491.SGD","BK4532","TBXU","LU1066053197.SGD","MEDI","BMED","LU0114720955.EUR","LU2112291526.USD","LU1571399168.USD","LU2324357040.USD","LU0965508806.USD","LU1430594728.SGD","LU0882574055.USD","LU1023059063.AUD","BK4550","LU2468319806.SGD","IE00BKVL7J92.USD","TMED","LU1037948897.HKD","LU0965509010.AUD","BK4578","LU0861579265.USD","LU2087621335.USD","LU1066051498.USD","BK4588","LU1674673428.USD","LU1934455194.USD","IE00BSNM7G36.USD","IE0002270589.USD","LU0234570918.USD","IE00B7SZLL34.SGD","IE00B3T34201.USD","BIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134733225","title":"Shield Therapeutics宣佈全面接管ACCRUFeR美國商業化運營","url":"https://stock-news.laohu8.com/highlight/detail?id=1134733225","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134733225?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 23:37","pubTimestamp":1787845053,"startTime":"0","endTime":"0","summary":"路透社8月27日消息——Shield Therapeutics PLC于当日发布重大声明，透露其即将全面接管ACCRUFeR在美国市场的商业运营权，预计交割日期定于2026年9月30日。据悉，该公司已与Viatris Inc.达成一项重要协议。值得关注的是，这笔交易中Shield无需向Viatris支付任何前期款项。Shield Therapeutics进一步表示，此项交易将立即为公司带来增值效应。本次协议标志着Shield Therapeutics在美国市场战略布局的关键一步，展现了公司对其核心产品ACCRUFeR商业潜力的坚定信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","LU2087621335.USD","BK4007","BK4585","LU1839511570.USD","BK4588","VTRS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}]}}